In November, results from a clinical phase Ib study with Stayble Therapeutics injectable drug candidate STA363. The candidate, which is being developed as a treatment for chronic pain related to herniated discs, was shown to be safe and tolerable. In addition, the STA363-treated group showed a statistically significant reduction in disc height compared to the placebo group. Such volume reduction is a prerequisite for reducing herniated disc-related pain.
Hoping for agreement in 2025
In addition to the clinical program, Stayble is working with its transaction advisor to identify the right partner for continued development. Both non-confidential and in-depth confidential discussions with stakeholders are currently underway. The strong interest strengthens the company's hopes of entering into an agreement based on available Phase Ib results.
– We are experiencing strong momentum, with significant interest from several pharmaceutical companies confirming the great potential of STA363. We are positive about the ongoing discussions and look forward to the possibility of concluding a deal or strategic collaboration with a relevant counterparty in 2025, writes the CEO Andreas Gerward in a comment.